AI Article Synopsis
Article Abstract
Background: Topical delgocitinib (JTE-052), a novel Janus kinase inhibitor, had been shown to be clinically effective in adults with atopic dermatitis (AD). However, the efficacy of topical delgocitinib in pediatric patients with AD remained unclear.
Objective: We sought to evaluate the efficacy and safety of delgocitinib ointment in pediatric patients with AD.
Methods: In this phase 2 clinical study (JapicCTI-173553) Japanese patients aged 2 through 15 years with AD were randomized in a 1:1:1 ratio to receive 0.25% or 0.5% delgocitinib ointment or vehicle ointment twice daily for 4 weeks. The primary efficacy end point was the percentage change from baseline in the modified Eczema Area and Severity Index score at the end of treatment (EOT).
Results: At EOT, modified Eczema Area and Severity Index scores in both delgocitinib groups were significantly reduced compared with that in the vehicle group. The least-squares mean percentage change from baseline was -54.2% in the 0.25% group and -61.8% in the 0.5% group versus -4.8% in the vehicle group (P < .001 for both comparisons). Similarly, all other efficacy parameters, including Investigator's Global Assessment and pruritus scores, in both delgocitinib groups were significantly improved compared with those in the vehicle group at EOT. Adverse events in both delgocitinib groups were mild in severity, and no serious adverse events were reported.
Conclusions: Delgocitinib ointment improved clinical signs and symptoms in pediatric patients with AD and was well tolerated. These study results indicate that delgocitinib ointment can be a promising therapeutic option for pediatric patients with AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2019.08.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
English version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus.
View Article and Find Full Text PDFPost-hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials.
Pediatr Int
October 2024
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Article Synopsis
- Delgocitinib ointment is primarily recommended at a 0.25% concentration for children, but a 0.5% formulation may be considered based on symptom severity, with unclear safety data when used with other treatments.
- A post-hoc analysis compared the efficacy and safety of 0.25% and 0.5% formulations over up to 4 and 56 weeks in pediatric patients, focusing on combinations with topical corticosteroids and tacrolimus.
- Results showed the 0.5% formulation was more effective for mild cases, while both dosages were well-tolerated with no significant safety differences, even when used alongside other medications.
Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans.
Sci Transl Med
June 2024
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Article Synopsis
- Epidermal growth factor receptor inhibitors (EGFRis) can treat various cancers, but they often cause severe skin rashes that negatively impact patients' quality of life.
- Research shows that the activation of keratinocytes, along with S100A9 protein induction, happens early in the development of these rashes, which leads to an immune response that exacerbates the skin condition.
- Treatment with topical JAK inhibitors has been effective in reducing the severity of the rash in animal models and showed promising results in a pilot clinical trial, indicating potential management strategies for this side effect.
Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis.
Front Pharmacol
April 2024
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Article Synopsis
- - We conducted a Bayesian network meta-analysis on 13 trials with 3,613 patients to evaluate the efficacy and safety of new JAK inhibitors for treating moderate-to-severe alopecia areata, finding that brepocitinib 30mg was the most effective in improving SALT scores.
- - Deuruxolitinib 12mg showed strong effectiveness for severe cases, but it also had a higher likelihood of causing adverse events, while ritlecitinib 50mg appeared to balance safety and efficacy better among high-dose oral options.
- - The study highlights a need for more extensive head-to-head trials over longer periods to validate these findings and further assess the long-term safety of these treatments for alopecia
Alopecia areata in a patient with cytotoxic T lymphocyte antigen-4 haploinsufficiency successfully treated with topical delgocitinib ointment.
J Eur Acad Dermatol Venereol
January 2024
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!